Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 20Ureteral Neoplasms 7Urologic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Urogenital Neoplasms 2Urethral Neoplasms 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 3pembrolizumab 2cabozantinib 2aldesleukin 2Specimen Handling 2CTLA-4 Antigen 2Adoptive Transfer 2niraparib 1lenvatinib 1entinostat 1enfortumab vedotin 1dostarlimab 1cemiplimab 1bintrafusp alfa protein, human 1avelumab 1Psychiatric Nursing 1Platinum 1Physical Therapy Modalities 1Palliative Care 1Paclitaxel 1Gemcitabine 1Fluorodeoxyglucose F18 1FAPI-46 1Cisplatin 1CP protocol 1Biopsy 1BAY 1895344 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Penile Neoplasms × enfortumab vedotin × 1 year × Clear all
NCT06104618 2025-12-11

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Mayo Clinic

Phase 2 Recruiting
28 enrolled
Genitourinary

Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡